Axogen, Inc. announces the appointment of Adrian Tyndall, M.D. MPH, FACEP to its Board of Directors and the retirement of founding Director Mark Gold, M.D.
October 31 2022 - 7:00AM
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and
marketing innovative surgical solutions for peripheral nerve
injuries, today announced that effective December 13, 2022 (the
“Effective Date”), Adrian Tyndall, M.D., MPH, FACEP has been
appointed as an independent member to the company’s board of
directors and will serve on the Quality, Compliance, and Portfolio
Management Committee. The company also announced today that Mark
Gold, M.D. a founding director, will retire from the board of
directors on the Effective Date. Dr. Gold will continue to serve
the Board of Directors until that time.
“We are delighted to welcome Dr. Tyndall to the board. His
wealth of experience in emergency care, trauma research, and
academia will be of tremendous value in supporting our mission to
restore nerve function and quality of life to patients with
peripheral nerve injuries,” commented Karen Zaderej, chairman, CEO,
and president. “On behalf of the board of directors, I want to
thank Dr. Gold for his dedication and innumerable contributions to
Axogen. He has been instrumental in guiding our organization since
the beginning and we wish him all the best in his retirement.”
Joseph “Adrian” Tyndall, MD, MPH, FACEP is a recognized leader
in emergency medicine, educational leadership and research and is
currently the Executive Vice President for Health Affairs and Dean
of Morehouse School of Medicine. Previously, Dr. Tyndall spent more
than 13 years as Professor, Emergency Medicine Department Chair,
Trauma Researcher and Interim Dean and Associate Vice President at
the University of Florida College of Medicine and UF Health. A
graduate of the University of Maryland School of Medicine including
the emergency medicine residency program at the University of
Maryland Medical System, Dr. Tyndall received a master’s degree in
Health Services Management and Health Policy from Columbia
University, and a bachelor’s degree in Chemistry from The George
Washington University. He is board-certified in emergency medicine
by the American Board of Emergency Medicine and an American College
of Emergency Physicians Fellow. Dr. Tyndall is the current
President of the Society for Academic Emergency Medicine Foundation
and was also recently elected to serve a two year term on the
administrative board of the Council of Deans of the Association of
American Medical Colleges (AAMC). He has researched and published
on traumatic and ischemic brain injuries, is an editor for a
leading emergency medicine reference textbook and is known
worldwide in the field of emergency medicine.
“I am pleased to join the Axogen Board of Directors and
contribute towards the company’s mission,” said Dr Tyndall. “As an
emergency care and trauma researcher, I am fascinated by the
science and potential improvements for treatments to traumatic
injuries. Axogen is a leading innovator in traumatic injury nerve
repair as well as a pioneer in other applications, and I am looking
forward to joining the board.”
About AxogenAxogen (AXGN) is the
leading company focused specifically on the science, development,
and commercialization of technologies for peripheral nerve
regeneration and repair. Axogen employees are passionate about
helping to restore peripheral nerve function and quality of life to
patients with physical damage or transection to peripheral nerves
by providing innovative, clinically proven, and economically
effective repair solutions for surgeons and health care providers.
Peripheral nerves provide the pathways for both motor and sensory
signals throughout the body. Every day, people suffer traumatic
injuries or undergo surgical procedures that impact the function of
their peripheral nerves. Physical damage to a peripheral
nerve, or the inability to properly reconnect peripheral nerves,
can result in the loss of muscle or organ function, the loss of
sensory feeling, or the initiation of pain.
Axogen's platform for peripheral nerve repair
features a comprehensive portfolio of products, including Avance®
Nerve Graft, a biologically active off-the-shelf processed human
nerve allograft for bridging severed peripheral nerves without the
comorbidities associated with a second surgical site; Axoguard
Nerve Connector®, a porcine submucosa ECM coaptation aid for
tensionless repair of severed peripheral nerves; Axoguard Nerve
Protector®, a porcine submucosa ECM product used to wrap and
protect damaged peripheral nerves and reinforce the nerve
reconstruction while preventing soft tissue attachments; and
Axoguard Nerve Cap®, a porcine submucosa ECM product used to
protect a peripheral nerve end and separate the nerve from the
surrounding environment to reduce the development of symptomatic or
painful neuroma. The Axogen portfolio of products is available in
the United States, Canada, Germany, the United Kingdom, Spain,
South Korea, and several other countries.Contact:Axogen,
Inc.Ed Joyce, Director, Investor
Relationsejoyce@axogeninc.com
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From May 2024 to Jun 2024
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Jun 2023 to Jun 2024